Comparing argon plasma coagulation and endoscopic mucosal resection for small gastric adenomas
A Multicenter, Randomized, Single-Blinded Trial Comparing Argon Plasma Coagulation and Endoscopic Mucosal Resection for Gastric Adenoma With Low-Grade Dysplasia
This trial will test whether argon plasma coagulation or endoscopic mucosal resection works better to treat small (≤1 cm) gastric adenomas with low-grade dysplasia.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 160 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Samsung Medical Center Academic / other |
| Locations | 3 sites (Goyang-si and 2 other locations) |
| Trial ID | NCT07161479 on ClinicalTrials.gov |
What this trial studies
Gastric adenomas with low-grade dysplasia are precancerous lesions for which management varies internationally. This interventional trial assigns patients with lesions ≤1 cm to receive either argon plasma coagulation (APC) or endoscopic mucosal resection (EMR) and follows them for completeness of treatment, complication rates, and recurrence. EMR removes the lesion for full pathological assessment but can be more technically demanding, while APC is less invasive and quicker but provides less tissue for pathology. The study aims to provide head-to-head clinical data to guide treatment choices for these small lesions.
Who should consider this trial
Good fit: Adults aged 20 years or older with a single gastric adenoma measuring ≤1 cm and confirmed low-grade dysplasia who are scheduled for endoscopic treatment and can give informed consent are ideal candidates.
Not a fit: Patients with high-grade dysplasia or gastric cancer, lesions larger than 1 cm, multiple adenomas, prior gastric treatment or gastrectomy, pregnancy, or uncontrolled serious medical conditions are unlikely to benefit from this trial.
Why it matters
Potential benefit: If positive, the trial could show that the less invasive APC offers similar cure rates with fewer complications or shorter procedures compared with EMR, expanding treatment options for patients.
How similar studies have performed: EMR and ESD are established and guideline-supported for resection of precancerous gastric lesions, while APC is commonly used in practice but lacks large randomized head-to-head evidence specifically for ≤1 cm low-grade dysplasia.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 20 years or older * Diagnosed with gastric adenoma with low-grade dysplasia measuring ≤ 1 cm on endoscopy * Scheduled to undergo endoscopic treatment * Able and willing to provide written informed consent Exclusion Criteria: * Previous treatment for gastric adenoma or gastric cancer * History of gastrectomy * Diagnosis of gastric cancer or high-grade dysplasia at the time of enrollment * Presence of multiple gastric adenomas * Pregnant, breastfeeding, or possibility of pregnancy * Uncontrolled chronic illnesses that may interfere with trial participation (e.g., uncontrolled hypertension, uncontrolled diabetes, chronic kidney disease, ascites, heart failure, psychiatric disorders)
Where this trial is running
Goyang-si and 2 other locations
- National Cancer Center — Goyang-si, South Korea (Recruiting)
- Kangbuk Samsung hospital — Seoul, South Korea (Recruiting)
- Samsung Medical Center — Seoul, South Korea (Recruiting)
Study contacts
- Principal investigator: Hyuk Lee, MD, PhD — Samsung Medical Center
- Study coordinator: Clinical Research Coordinator
- Email: minjicho630@naver.com
- Phone: 82-2-3410-6853
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.